MK-3682B clinical trials
Also written MK-3682B.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses MK-3682B is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MK-3682B
- 4
Studies by the year they started
4 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Grazoprevir (1) · Uprifosbuvir (1) · Elbasvir (1) · Ruzasvir (1)
Studies
Open first, then newest update. How each study uses MK-3682B is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02613403Written as MK-3682B
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332720Written as MK-3682B
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
- Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)CompletedPhase 1Merck Sharp & Dohme LLCNCT02661126Written as MK-3682B